A Phase Ib/II clinical trial of DDFPe as a radiosenzitizer in glioblastoma

Tumor hypoxia limits the response of glioblastoma multiforme (GBM) to radiotherapy and chemotherapy. The purpose of this study was to evaluate the safety and efficacy of DDFPe in chemoradiation treatment of GBM. Although small, this trial shows that DDFPe used as a radiosensitizer appears to be safe and may provide some survival benefit. The FDA has allowed a Phase II clinical trial to assess its effectiveness.


Read full entry